Blood cancers

Study shows indicators of venetoclax response in therapy-related myeloid neoplasm

Venetoclax can induce deep remission in a subset of patients with aggressive therapy-related myeloid neoplasm (t-MN), according to research conducted at the Mayo Clinic and the Central Adelaide Health Network. A retrospective review of 367 WHO-defined cases of t-MN was presented at the 63rd ASH Annual Meeting and Exposition. The Mayo’s Dr Mithun Shah told ...

Already a member?

Login to keep reading.

© 2022 the limbic